(Q42623524)

3 November 2017

Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma (English)

1 reference

3 November 2017

1 reference

Konstas AG

1

1 reference

3 November 2017

Maltezos A

2

1 reference

3 November 2017

Bufidis T

3

1 reference

3 November 2017

Hudgins AG

4

1 reference

3 November 2017

Stewart WC

5

1 reference

3 November 2017

1 February 2000

1 reference

3 November 2017

1 reference

3 November 2017

14 ( Pt 1)

1 reference

3 November 2017

73-77

1 reference

https://scigraph.springernature.com/pub.10.1038/eye.2000.16

3 November 2017

0 references

cites work

Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma.

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

Analyzing data from ordered categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. The Dorzolamide Additivity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

MK-507 (L-671,152), a topically active carbonic anhydrase inhibitor, reduces aqueous humor production in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

A comparison of dorzolamide and timolol in patients with pseudoexfoliation and glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1038%2FEYE.2000.16

7 January 2021

Identifiers

DOI

10.1038/EYE.2000.16

1 reference

Dimensions Publication ID

3 November 2017

0 references

1 reference